Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
72 Cards in this Set
- Front
- Back
|
Melphelan
|
alkylating agent → mustard. Multiple myeloma
|
|
|
Chlorambucil
|
alkylating agent → mustard. Chronic lymphoblastic leukemia
|
|
|
Busulfan
|
alkylating agent → mustard
|
|
|
Cyclophosphamide
|
alkylating agent → mustard. Mensa reversal
|
|
|
Ifosfamide
|
alkylating agent → mustard. Methylene blue reversal
|
|
|
Bendamustine
|
alkylating agent/antimetabolite → mustard
|
|
|
Loumustine
|
alkylating agent → nitrosuera. Releases isocynate
|
|
|
Caramustine
|
alkylating agent → nitrosourea
|
|
|
Streptozocin
|
alkylating agent → nitrosurea
|
|
|
Dacarbazine
|
alkylating agent →triazene
|
|
|
Temazolamide
|
alkylating agent → triazene
|
|
|
Cisplatin
|
alkylating agent → platinum compound. Neuro/oto/nephrotoxic
|
|
|
Carboplatin
|
alkylating agent → platinum compound. Myleosupression
|
|
|
Oxaliplatin
|
alkylating agent → platinum compound
|
|
|
Procarbazine
|
alkylating agnet. MAOI parallels
|
|
|
Methotrexate
|
antimetabolite → folate antagonist. Inhibits dihydrofolate reductase
|
|
|
Premetrexed
|
anti-metabolite → folate antagonist. Inhibits by purine and pyrimidine synthesis. Pretreat with B12 and folic acid
|
|
|
5-FU
|
anti-metabolite → pyrminidine antagonist. More effective with continuous administration
|
|
|
Cytarabine
|
anti-metabolite → pyrmidine antagonis. Backbone of AMC and ALL treatment.
|
|
|
Gemcitabine
|
anti-metabolite → pyrmidine antagonist. Locks up dAN polymerase. Broad spectrum on solid tumors
|
|
|
6-mercaptropurine
|
anti-metabolite → purine antagonist. Myelosupressive, metabolized by Xanthine oxidase
|
|
|
6-thiogunine
|
anti-metabolite → purine antagonist. More potent than 6-MP. More GI toxic
|
|
|
pentostatin
|
anti-metabolite → purine antagonist. Blocks conversion of adenosine to inosine by adenosine deaminase.
|
|
|
flurdarabine
|
anti-metabolite → purine antagonist. Inhibits DNA pol and ribonucleotide reductase
|
|
|
cladribine
|
anti-metabolite → purine antagonist Inhibits DNA pol and ribonucleotide reductase
|
|
|
clofarabine
|
anti-metabolite → purine antagonist. Inhibits DNA pol and ribonucleotide reductase
|
|
|
nelarabine
|
anti-metabolite → purine antagonist. Inhibits DNA pol and ribonucleotide reductase
|
|
|
hydroxyurea
|
analog of urea. Inhibits rebonucleotide reductase
|
|
|
doxorubicin
|
tumor antibiotic → anthracycline. Intercalate, inhibit topoisomerase II, free radical formation. Breast cancer.
|
|
|
idarubicin
|
tumor antibiotics → anthracyclin. Intercalate, inhibit topoisomerase II, free radical formation.
|
|
|
daunorubicin
|
tumor antibiotics → anthracycline. Intercalate, inhibit topoisomerase II, free radical formation.
|
|
|
epirubicin
|
tumor antibiotics → anthracycline. Intercalate, inhibit topoisomerase II, free radical formation.
|
|
|
mitoxantrone
|
tumor antibiotic → anthracenedione. DNA intercalation and topoisomerase II inhibition
|
|
|
bleomycin
|
tumor antibiotic. Partial DNA intercalation, oxygen bound by free reactive free radicals
|
|
|
etoposide
|
topoisomerase inhibitor (G2) → podophyllotoxin
|
|
|
Teniposide
|
topoisomerase inhibitor (G2) → podophyllotoxin
|
|
|
Toptecan
|
topoisomerase inhibitor (G2) → camptothecin
|
|
|
Irinotecan
|
topoisomerase inhibitor (G2) → camptothecin. Colorectal cancer
|
|
|
Vincrinstine
|
antimicrotubule → vinca
|
|
|
vinorelbine
|
antimicrotubule → vinca
|
|
|
vinblastine
|
antimicrotubule → vinca
|
|
|
paxlitaxel
|
antimicrotubule → taxane
|
|
|
docetaxel
|
antimicrotubule → taxane
|
|
|
ixabepilone
|
antimicrotubule → epothilone
|
|
|
l-asparaginase
|
its own thing. Do not administer on same day as methotrexate
|
|
|
imatinib
|
tyrosine kinase inhibitor. Peripheral fluid retention
|
|
|
dasatinib
|
tyrosine kinase inhibitor. Central fluid retention
|
|
|
nilotinib
|
tyrosine kinase inhibitor. No fluid retention
|
|
|
azacitidine
|
hypomethylating agent
|
|
|
decitabine
|
hypomethylating agent
|
|
|
vorinostat
|
histone diacetylase inhibitor. Increased transcription → apoptosis
|
|
|
romidepsin
|
histone diacetylase inhibitor. Increased transcription → apoptosis
|
|
|
bortezomib
|
proteasome inhibitor
|
|
|
temsirolimus
|
mTOR inhibitor
|
|
|
everolimus
|
mTOR inhibitor
|
|
|
ATRA
|
biologic response modifier, doesn’t kill cells. Allows for normal growth
|
|
|
Arsenic trioxide
|
biologic response modifier, second line agent in APL when ATRA/antracycline therapy fails
|
|
|
Rituximab
|
CD-20 monoclonal antibody
|
|
|
Tamoxifen
|
partial estrogen agonist (bone/uterus), antagonist in breast tissue
|
|
|
Anastrozole
|
aromatase inhibitor
|
|
|
Letrozole
|
aromatase inhibitor
|
|
|
Exemestane
|
aromatase inhibitor
|
|
|
Leuprolide
|
gonadotropin agonist
|
|
|
Goserelin
|
gonadotropin agonist
|
|
|
Triptorelin
|
gonadotropin agonist
|
|
|
Bicalutamide
|
antiandrogen
|
|
|
Filgrastrim
|
G-CSF
|
|
|
Saragramostim
|
GM-CSF
|
|
|
Peg-Filgrastim
|
|
|
|
Plerixafor
|
growth factor that casues leukocytosis
|
|
|
Amifostine
|
free radical scavenger. Given with cisplatin to prevent cardiac toxicity
|
|
|
Palifermin
|
keratinocyte growth factor.
|
